AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03855293 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rhexis protection shield
Description: In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
Study NCT01102699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, hrG-CSF
Description: Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
Study NCT02101580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study NCT02108184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy 10 days
Description: (pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
Study NCT02108184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy 14 days
Description: (pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
Study NCT02108184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy 10 days
Description: (pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
Study NCT02108184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy 14 days
Description: (pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
Study NCT03513133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: working memory training
Description: Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
Study NCT01795911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda
Study NCT01795911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribasphere
Study NCT01795911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT03753191 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
Study NCT03753191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
Study NCT05544279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education is given about the focused disease and its nursing care management
Study NCT02296931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Standard IV Saline Fluids
Study NCT02296931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
Study NCT02369198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TargomiRs
Description: TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected.
Study NCT02943135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine in-situ gel
Description: lidocaine in-situ gel
Study NCT02943135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in-situ gel
Description: placebo in-situ gel
Study NCT04392427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
Description: Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days
Study NCT03685201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Juice1
Description: 100% Orange Juice
Study NCT03685201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange Juice2
Description: 100% Orange Juice with enzyme-treated orange pomace fiber
Study NCT03685201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Raw Orange
Description: Raw Orange
Study NCT00338312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
Study NCT00338312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch changed twice a week for one year
Study NCT01191944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole immediate release tablet
Description: 0.375mg-4.5mg(daily dose), three times a day
Study NCT01191944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole extended release tablet
Description: 0.375mg-4.5mg, once a day
Study NCT01708967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pretreatment method for transnasal endoscopy
Description: Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity.
Study NCT02000765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 for Injection
Description: GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
Study NCT02000765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Capsule
Description: GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
Study NCT04015908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 100mg
Study NCT04015908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 325mg
Study NCT04015908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 50 mg
Study NCT04015908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone 5-10 mg
Study NCT04015908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: Percocet (oxycodone 5mg/acetaminophen 325 mg)
Study NCT02143921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training intervention
Description: Intervention group service providers received intervention training
Study NCT00755443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Drug eluting stent implantation
Study NCT00755443 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bare metal stent
Study NCT03783429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Digoxin tablets will be given orally
Study NCT03783429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo tablets will be given orally
Study NCT03935438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
Study NCT01620294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal wall closure
Description: triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
Study NCT01620294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical site infection
Description: triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
Study NCT01443897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,000 IU vitamin D2
Description: capsule containing 1,000 IU vitamin D2
Study NCT01443897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: 0 IU vitamin D2
Study NCT01443897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo capsule
Description: 0 IU vitamin D2
Study NCT02994667 — intervention group
Intervention type: DEVICE
Intervention: Permanent Pacemaker Placement
Study NCT03491566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic Pilates Group
Description: Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises.
Study NCT03491566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group
Description: Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
Study NCT00973544 — intervention group
Intervention type: OTHER
Intervention: Cultures taken from the drain discharge
Description: Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
Study NCT01727648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT in sequential combination with dCIT
Description: The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
Study NCT01727648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed Constraint-Induced Therapy
Description: The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
Study NCT03567278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TA™
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
Study NCT01662388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Separation ring
Description: Separation ring placed along with automatrix band
Study NCT01662388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: automatrix band
Description: band placed with a tightening device
Study NCT01662388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatrix band
Description: band placed with a tightening device
Study NCT01097811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: 250 mg orally q.i.d.
Study NCT01097811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Description: 1 g orally q.i.d.
Study NCT02022670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic sodium nitrite capsules
Study NCT02022670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: 80 mg/d or 160 mg/d
Study NCT03552276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 I (Tildrakizumab 200 mg)
Description: injection
Study NCT03552276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 II (Tildrakizumab 100 mg)
Description: injection
Study NCT03999372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronan binding system
Description: Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
Study NCT03999372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Normal ICSI procedure
Study NCT02406092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab SC 1400 mg
Study NCT02406092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per standard local practice.
Study NCT02406092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per standard local practice.
Study NCT02406092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered as per standard local practice.
Study NCT02406092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as per standard local practice.
Study NCT02406092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as per standard local practice.
Study NCT01449760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
Study NCT01449760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
Study NCT02506270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airseal Trocar
Description: 28 patients are treated with the AirSeal insufflation and trocar system
Study NCT02506270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: conventional trocar
Description: 28 patients are treated with a conventional insufflation and trocar system
Study NCT04366024 — intervention group
Intervention type: OTHER
Intervention: other
Description: clinical diagnosis
Study NCT03214172 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15/20 mg
Study NCT02540031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional oral preparation (3L of PEG+Asc, Coolprep®)
Description: The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study NCT02540031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral preparation (2L of PEG+Asc, Coolprep®)
Description: The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study NCT02025504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColoWrap
Description: ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
Study NCT02025504 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ColoWrap
Description: ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
Study NCT01727648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Therapy
Description: Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
Study NCT01727648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose-matched control therapy
Description: Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
Study NCT00945061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intracavitary balloon brachytherapy
Description: Patients undergo brachytherapy
Study NCT00945061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiation therapy
Description: Patients undergo radiotherapy
Study NCT05576168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: overexpression STRA6/miRNA3
Description: RBP4 express in patients with T2DM or not
Study NCT05576168 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: overexpression STRA6/miRNA3
Description: RBP4 express in patients with T2DM or not
Study NCT02864186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Women wont use support bra 24 hours a days for six months
Study NCT02864186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgical support bra
Description: Women will use surgical support bra 24 hours a day for six months
Study NCT02864186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: common support bra
Description: Women will use common support bra 24 hours a day for six months
Study NCT03200639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined training
Description: The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.